(Date:10/6/2008)...money, since side effects can affect length of sta...thDay News) -- Simple changes to hospital procedur...ren suffer while on opiates to relieve pain, a new...oration between 14 U.S. children,s hospitals, docu...aused by the pain relievers under these new proced...
(Date:10/6/2008).../PRNewswire-FirstCall/ -- HealthSouth,Corporation ...reviously,publicized investor meeting in New York ...8 at 8:30 a.m. EST at the Grand Hyatt New York, lo...g is as follows:, 8:00 a.m. Continental Break... Executive Officer -- HealthSouth Ove...
(Date:10/6/2008)...swire-USNewswire/ -- The United States has,interve...g that they,submitted false claims to Medicare ari...of sham durable medical equipment (DME) suppliers,...nies are McKesson Corporation,McKesson Medical-Su...,Golden Gate Ancillary LLC, Beverly Enterprises In...
(Date:10/6/2008)...wire/ -- Developed in collaboration with,Siemens(R...introducing,Revolutionary Breast Surface Imaging a...fice of Dr. Steve Laverson this week in Encinitas,...its kind, and is based on,breakthrough image captu...ive proprietary software. The XS-300(TM) platform ...
Breaking Medicine News(10 mins):Health News:Hospital Fixes Cut Opiate Errors in Kids 2Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Plan Your Breasts in 3-D 2(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
(Date:10/7/2008)...trolled Phase II Study Shows Statisticall...N VIEW, California, October 7 /- BN,I...se II data from the,therapeutic prostate cancer va...d as part of the recently entered partnership with...The results from the Phase II prospective randomiz...
(Date:10/7/2008)...for Use on the GeneXpert(R) ...wswire-FirstCall/ -- Cepheid (Nasdaq:,CPHD) today ...European CE,IVD Mark product under the European Di...e test delivers rapid detection of vanA and/or van...ancomycin-resistant,enterococci (VRE) -- one of th...
(Date:10/6/2008)...ll/ -- Pharmasset, Inc.,(Nasdaq: VRUS ) announces...mpany as Vice President of Investor Relations and ...sible for all investor relations,functions and wil...Leutzinger., Most recently, Dr. Smith was a Vice ...rgan Securities, and has been an analyst in the se...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 1Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 2Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 3Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 4Inquiring minds want to know about cotton fleahoppers 252 1Inquiring minds want to know about cotton fleahoppers 252 2Inquiring minds want to know about cotton fleahoppers 252 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 1Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 4Saflink and IdentiPHI Announce Merger Agreement 251 1Saflink and IdentiPHI Announce Merger Agreement 251 2Saflink and IdentiPHI Announce Merger Agreement 251 3Saflink and IdentiPHI Announce Merger Agreement 251 4Saflink and IdentiPHI Announce Merger Agreement 251 5...NESS WIRE)--Apr 3, 2007 -,Icagen, Inc. (NASDAQ: IC...ng of the independent Data Monitoring Committee,("...formerly,ICA-17043) for the treatment of sickle ce... trial be terminated because of the low,probabilit...mary,endpoint. In making their recommendation, the...
...Newswire-FirstCall/ --,SuperGen Inc. announced tod... American Association for Cancer Research,Annual M...tations,will focus on data concerning many of Supe...d tyrosine kinase inhibitor compound,MP470 and it...olved,in cancer cell drug resistance. Presentation...
Other Medicine Technology:Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection.
Triad Plus Sterile Isopropyl Alcohol 70% USP Swabsticks are primarily used as a topical antiseptic prior to administering injections. They are gamma sterilized to meet AAMI/ANSI/ISO 11137 standar
Aplicare's Saturated Swabsticks are packaged in easy open, single-use foil-laminated pouches. Each 4 inch Swabstick is saturated with precisely the correct amount of solution. Each package is termina
BD Persist contains 70% alcohol and 10% povidone iodine formulated in a unique polymer base, forming a barrier on the skin. The barrier creates a protective environment for the povidone iodin
Medicine Products: